Presentation is loading. Please wait.

Presentation is loading. Please wait.

Farmer et al Supplementary Figure 1 KU0058684 PARP-1 IC 50 = 3.2nM KU0058948 PARP-1 IC 50 = 3.4nM KU0051529 PARP-1 IC 50 = 730nM a b 0 0.001 0.01 0.1 1.

Published byOphelia Evans Modified over 8 years ago

Similar presentations

Presentation on theme: "Farmer et al Supplementary Figure 1 KU0058684 PARP-1 IC 50 = 3.2nM KU0058948 PARP-1 IC 50 = 3.4nM KU0051529 PARP-1 IC 50 = 730nM a b 0 0.001 0.01 0.1 1."— Presentation transcript:

1 Farmer et al Supplementary Figure 1 KU0058684 PARP-1 IC 50 = 3.2nM KU0058948 PARP-1 IC 50 = 3.4nM KU0051529 PARP-1 IC 50 = 730nM a b 0 0.001 0.01 0.1 1 10 100 0.0001 0.00001 [KU0058684] (  M) 0 0.001 0.01 0.1 1 10 100 [KU0058948] (  M) IC 50 = 6nM 0 20 40 60 80 100 % activity [KU0058948] (M) 10 -4 10 -2 10 0 10 1 10 -3 10 -1

2 1h 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction 24h 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction 4h 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction VC8 BAC VC8 log surviving fraction 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction 10 -7 10 -6 10 -5 10 -4 0 conc (M) D3 Cre15 Cre24 10 -4 log surviving fraction 10 -9 10 -8 10 -7 10 -6 10 -5 0 conc (M) log surviving fraction 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) 11CO Cre6 Cre10 1h4h24h Farmer et al Supplementary Figure 2 a b

3 a 10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction 10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction 10 -11 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 0 conc (M) log surviving fraction KU0058684KU0058948KU0051529 VC8 BAC VC8 b KU0051529 conc (M) log surviving fraction 0 10 -8 10 -7 10 -6 10 -4 0 10 -9 10 -5 10 -8 10 -7 10 -6 10 -4 0 10 -9 10 -5 conc (M) KU0058948 log surviving fraction 0 MCF7-3.23 MCF7-scrambled Farmer et al Supplementary Figure 3

4 0 1 2 3 010nM 1M1M 0 1M1M Brca1 wild-type Brca1 deficient KU0058684 concentration Number per cell Mean number of chromatid breaks Mean number of complex chromatid rearrangements 0 1 2 3 010nM0 Brca2 wild-type Brca2 deficient a Farmer et al Supplementary Figure 4

5 b 100 75 50 25 0 010 -9 10 -8 10 -7 10 -6 10 -5 KU0058684 concentration (M) 100 75 50 25 0 010 -9 10 -8 10 -7 10 -6 10 -5 KU0058684 concentration (M) % of cells with >5  H2AX foci 11CO Cre10 D3 Cre24

6 Wild-typeBrca1 deficientBrca2 deficient 0 10 0 10 0 10 0 10 20 30 40 50 60 70 80 90 100  M KU0058684 % of cells with >5  H2AX foci c Farmer et al Supplementary Figure 4 pSUPER-eCFP-control pSUPER-eCFP-Parp-1 d % of cells with >5  H2AX foci pSUPER- eCFP-control pSUPER- eCFP-Parp-1 0 10 20 30 40 50 60

7 0 1 2 5 10 0 10 0 10 10 0 20 40 60 80 100  M KU0058684  M KU0051529 Wild-typeBrca1 deficientBrca2 deficientWild-type % of cells with > 5 Rad51 foci e Farmer et al Supplementary Figure 4

Download ppt "Farmer et al Supplementary Figure 1 KU0058684 PARP-1 IC 50 = 3.2nM KU0058948 PARP-1 IC 50 = 3.4nM KU0051529 PARP-1 IC 50 = 730nM a b 0 0.001 0.01 0.1 1."

Similar presentations

00.111000.1110 A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S1 0.004.01.040.01.030.10.313100.01.11.

A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S
Supplemental figure A FA-D2 +FANCD2 FA-D2 +FANCD2(K561R) No HU 0.1mM HU S phase: 43%S phase: 34.7% S phase: 30.8% S phase: 52.7%S phase: 25.4%S phase:

Supplemental figure A FA-D2 +FANCD2 FA-D2 +FANCD2(K561R) No HU 0.1mM HU S phase: 43%S phase: 34.7% S phase: 30.8% S phase: 52.7%S phase: 25.4%S phase:
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Compound 5 Structure hLDHA IC 50 0.032 ± 0.016 µM hLDHB IC 50 2.512 ± 0.07 µM Supplementary Figure S1.

Compound 5 Structure hLDHA IC ± µM hLDHB IC ± 0.07 µM Supplementary Figure S1.
Supplementary Figure 1. Suzuki et al. DAPI/BrdU BrdU 24 hrs 48 hrs 72 hrs.

Supplementary Figure 1. Suzuki et al. DAPI/BrdU BrdU 24 hrs 48 hrs 72 hrs.
MDA-MB-468 48h MDA-MB-231 48h a MDA-MB-231 72h MDA-MB-468 MDA-MB-436 48h MDA-MB-436 72h MCF-7 48h MCF-7 72h b c ef g h MDA-MB-468 72h clomipramine.

MDA-MB h MDA-MB h a MDA-MB h MDA-MB-468 MDA-MB h MDA-MB h MCF-7 48h MCF-7 72h b c ef g h MDA-MB h clomipramine.
Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)

Condition MiaPaCa-2 Control Gem (100nm) AZD1775 (200nM) Gem + AZD1775 Panc-1 Control Gem (50nm) AZD1775 (200nM) Gem + AZD1775 Capan-1 Control Gem (50nm)
The reading is 7.38 mm. The reading is 7.72 mm.

The reading is 7.38 mm. The reading is 7.72 mm.
ΜΕΤΑΣΥΛΛΕΚΤΙΚΗ ΦΥΣΙΟΛΟΓΙΑ ΕΡΓΑΣΤΗΡΙΟ 3. Μετασυλλεκτική Εργ3-Λιοσάτου Γ.2 ΒΙΟΛΟΓΙΚΟΙ ΠΑΡΑΓΟΝΤΕΣ ΠΟΥ ΕΠΗΡΕΑΖΟΥΝ ΤΗ ΦΘΟΡΑ ΤΩΝ ΟΠΩΡΟΚΗΠΕΥΤΙΚΩΝ Αναπνοή Η λειτουργία.

ΜΕΤΑΣΥΛΛΕΚΤΙΚΗ ΦΥΣΙΟΛΟΓΙΑ ΕΡΓΑΣΤΗΡΙΟ 3. Μετασυλλεκτική Εργ3-Λιοσάτου Γ.2 ΒΙΟΛΟΓΙΚΟΙ ΠΑΡΑΓΟΝΤΕΣ ΠΟΥ ΕΠΗΡΕΑΖΟΥΝ ΤΗ ΦΘΟΡΑ ΤΩΝ ΟΠΩΡΟΚΗΠΕΥΤΙΚΩΝ Αναπνοή Η λειτουργία.
Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.

Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.
Supplementary Fig. 2 A B ** newly generated ISL1+ motor neurons (%)

Supplementary Fig. 2 A B ** newly generated ISL1+ motor neurons (%)
Supplementary Figure 1 Shiota et al.

Supplementary Figure 1 Shiota et al.
Effect of concentration of Halo-FGF1 and of Halo-FGF2 on their binding and diffusion in Rama 27 fibroblast pericellular matrix. Effect of concentration.

Effect of concentration of Halo-FGF1 and of Halo-FGF2 on their binding and diffusion in Rama 27 fibroblast pericellular matrix. Effect of concentration.
DNA damage foci in irradiated cells.

DNA damage foci in irradiated cells.
SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

SCLCs and LCNECs are sensitive to PARP inhibition in vitro.
Analysis of the effect of loss of Brca2 on in vivo somatic mutation frequency and mutation type. Analysis of the effect of loss of Brca2 on in vivo somatic.

Analysis of the effect of loss of Brca2 on in vivo somatic mutation frequency and mutation type. Analysis of the effect of loss of Brca2 on in vivo somatic.
Supplementary figure S1 by Shin et al.

Supplementary figure S1 by Shin et al.
Camptothecin‐induced DNA damage response is ataxia telangiectasia mutated dependent in post‐mitotic cells. Camptothecin‐induced DNA damage response is.

Camptothecin‐induced DNA damage response is ataxia telangiectasia mutated dependent in post‐mitotic cells. Camptothecin‐induced DNA damage response is.
Import of NH‐Idp3p‐, PTS‐1 (3HAD)‐ and PTS2 (3‐ketoacyl‐CoA thiolase)‐containing proteins in wild‐type, Δpex5 and Δpex7 cells. Import of NH‐Idp3p‐, PTS‐1.

Import of NH‐Idp3p‐, PTS‐1 (3HAD)‐ and PTS2 (3‐ketoacyl‐CoA thiolase)‐containing proteins in wild‐type, Δpex5 and Δpex7 cells. Import of NH‐Idp3p‐, PTS‐1.
A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

Similar presentations

Ads by Google